BamSEC and AlphaSense Join Forces
Learn More

Opko Health Inc.

NASDAQ: OPK    
Share price (12/20/24): $1.54    
Market cap (12/20/24): $1.051 billion
Search in Documents
Key Exhibits
External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

EX-2.1
from 8-K/A 89 pages Asset Purchase Agreement Dated as of March 27, 2024 by and Among Bioreference Health, LLC, Opko Health, Inc. and Laboratory Corporation of America Holdings
12/34/56
EX-2.1
from 8-K 89 pages Asset Purchase Agreement Dated as of March 27, 2024 by and Among Bioreference Health, LLC, Opko Health, Inc. and Laboratory Corporation of America Holdings
12/34/56
EX-2.1
from 8-K 67 pages Agreement and Plan of Merger Opko Health, Inc., Orca Acquisition Sub, Inc., Modex Therapeutics, Inc., and Sellers’ Representative Dated as of May 9, 2022
12/34/56
EX-2.1
from 8-K 109 pages Agreement and Plan of Merger and Reorganization by and Among Sema4 Holdings Corp., a Delaware Corporation, Orion Merger Sub I, Inc., a Delaware Corporation, Orion Merger Sub II, LLC, a Delaware Limited Liability Company, Genedx, Inc., a New Jersey Corporation, Genedx Holding 2, Inc., a Delaware Corporation, and Opko Health, Inc., a Delaware Corporation, Dated as of January 14, 2022
12/34/56
EX-2.1
from 8-K 93 pages Arrangement Agreement by and Among Opko Health, Inc., Opko Global Holdings, Inc. and Transition Therapeutics Inc. Dated as of June 29, 2016
12/34/56
EX-2.2
from 10-Q 18 pages [***] Indicates Portions of This Exhibit That Have Been Omitted and Filed Separately With the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment
12/34/56
EX-2.1
from 10-Q 28 pages Dated 5 May, 2015 (1) Sellers (2) Opko Ireland Limited (3) Opko Health, Inc. Agreement for the Sale and Purchase of Shares in Eirgen Pharma Limited McCann Fitzgerald Solicitors Riverside One Sir John Rogerson’s Quay Dublin 2 Bob\16793391.14 Contents
12/34/56
EX-2.1
from 8-K 90 pages Agreement and Plan of Merger by and Among Opko Health, Inc., Bamboo Acquisition, Inc. and Bio-Reference Laboratories, Inc. Dated as of June 3, 2015
12/34/56
EX-2.1
from 425 90 pages Agreement and Plan of Merger by and Among Opko Health, Inc., Bamboo Acquisition, Inc. and Bio-Reference Laboratories, Inc. Dated as of June 3, 2015
12/34/56
EX-2.10
from 10-Q 77 pages Share Purchase Agreement by and Among Cytochroma Inc., Cytochroma Holdings Ulc, Cytochroma Canada Inc. Cytochroma Development Inc. Proventiv Therapeutics, LLC Cytochroma Cayman Islands, Ltd., Opko Health, Inc. and Opko Ip Holdings, Inc. January 8, 2013
12/34/56
EX-2.9
from 10-K 43 pages Agreement and Plan of Merger
12/34/56
EX-2.8
from 10-Q 50 pages Stock Purchase Agreement
12/34/56
EX-2.7
from 10-Q 46 pages Stock Purchase Agreement
12/34/56
EX-2.6
from 10-K 39 pages Stock Purchase Agreement
12/34/56
EX-2.5
from 10-Q 50 pages Agreement and Plan of Merger
12/34/56
EX-2.4
from 10-Q/A 29 pages Confidential Material Omitted and Filed Separately With the Securities and Exchange Commission. Asterisks Denote Such Omissions
12/34/56
EX-2.4
from 10-Q 29 pages Confidential Material Omitted and Filed Separately With the Securities and Exchange Commission. Asterisks Denote Such Omissions
12/34/56
EX-2.3
from 10-Q 37 pages Purchase Agreement
12/34/56
EX-2.1
from 10-Q 39 pages Confidential Material Omitted and Filed Separately With the Securities and Exchange Commission. Asterisks Denote Such Omissions. Securities Purchase Agreement
12/34/56
EX-2.1
from 10-K 17 pages Amended and Restated Bylaws of Opko Health, Inc. (A Delaware Corporation) Effective: March 28, 2008
12/34/56